Rein Therapeutics (RNTX) Competitors $1.65 -0.07 (-4.07%) As of 04/16/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock RNTX vs. CYBN, FULC, TARA, PBYI, DERM, OGI, GLSI, LYEL, ACRS, and FDMTShould you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Cybin (CYBN), Fulcrum Therapeutics (FULC), Protara Therapeutics (TARA), Puma Biotechnology (PBYI), Journey Medical (DERM), Organigram (OGI), Greenwich LifeSciences (GLSI), Lyell Immunopharma (LYEL), Aclaris Therapeutics (ACRS), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Rein Therapeutics vs. Cybin Fulcrum Therapeutics Protara Therapeutics Puma Biotechnology Journey Medical Organigram Greenwich LifeSciences Lyell Immunopharma Aclaris Therapeutics 4D Molecular Therapeutics Cybin (NYSE:CYBN) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking. Which has more risk & volatility, CYBN or RNTX? Cybin has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Rein Therapeutics has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Is CYBN or RNTX more profitable? Cybin's return on equity of -37.58% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Rein Therapeutics N/A -74.08%-27.93% Which has better earnings and valuation, CYBN or RNTX? Cybin is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.38-1.70Rein TherapeuticsN/AN/A-$15.73M-$3.47-0.48 Does the MarketBeat Community prefer CYBN or RNTX? Cybin received 16 more outperform votes than Rein Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformCybinOutperform Votes16100.00% Underperform VotesNo VotesRein TherapeuticsN/AN/A Do analysts recommend CYBN or RNTX? Cybin presently has a consensus target price of $86.00, indicating a potential upside of 1,054.36%. Given Cybin's stronger consensus rating and higher possible upside, research analysts clearly believe Cybin is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Rein Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in CYBN or RNTX? 17.9% of Cybin shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 5.1% of Rein Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor CYBN or RNTX? In the previous week, Rein Therapeutics had 6 more articles in the media than Cybin. MarketBeat recorded 6 mentions for Rein Therapeutics and 0 mentions for Cybin. Rein Therapeutics' average media sentiment score of 0.92 beat Cybin's score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cybin Neutral Rein Therapeutics Positive SummaryRein Therapeutics beats Cybin on 8 of the 14 factors compared between the two stocks. Remove Ads Get Rein Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNTX vs. The Competition Export to ExcelMetricRein TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.29M$6.26B$5.28B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.536.6921.6517.68Price / SalesN/A222.70371.0992.89Price / CashN/A65.6738.1534.64Price / Book1.175.776.373.94Net Income-$15.73M$142.01M$3.20B$247.45M7 Day Performance5.77%5.79%3.76%3.17%1 Month Performance-18.72%-15.47%-10.49%-8.53%1 Year PerformanceN/A-10.99%10.39%0.32% Rein Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNTXRein TherapeuticsN/A$1.65-4.1%N/AN/A$36.29MN/A-0.539News CoverageCYBNCybin1.5447 of 5 stars$6.80+18.5%$86.00+1,164.7%N/A$146.04MN/A-1.5550High Trading VolumeFULCFulcrum Therapeutics2.1598 of 5 stars$2.69+2.3%$8.63+220.6%-58.7%$145.20M$80M-8.68100Short Interest ↓TARAProtara Therapeutics1.8495 of 5 stars$3.91+4.3%$22.50+475.4%+40.4%$143.76MN/A-1.3930Analyst ForecastNews CoveragePositive NewsGap UpPBYIPuma Biotechnology3.5297 of 5 stars$2.82+2.9%$7.00+148.2%-43.5%$139.90M$230.47M5.88200Analyst UpgradeNews CoverageDERMJourney Medical2.3987 of 5 stars$6.03-0.5%$9.88+63.8%+63.4%$139.32M$56.13M-6.4190Short Interest ↑OGIOrganigram0.6769 of 5 stars$1.03+6.2%N/A-44.7%$130.04M$166.12M-2.71860Positive NewsGLSIGreenwich LifeSciences1.9512 of 5 stars$9.86+5.8%$38.00+285.4%-38.7%$129.61MN/A-12.323Earnings ReportUpcoming EarningsGap DownLYELLyell Immunopharma3.214 of 5 stars$0.44+5.7%$1.00+128.1%-81.8%$129.46M$61,000.00-0.56270Analyst ForecastACRSAclaris Therapeutics2.3787 of 5 stars$1.15+6.5%$11.67+914.5%-7.4%$124.11M$18.72M-2.21100Positive NewsGap UpFDMT4D Molecular Therapeutics2.5717 of 5 stars$2.63+1.5%$26.71+915.8%-89.1%$121.77M$37,000.00-0.92120Positive News Remove Ads Related Companies and Tools Related Companies CYBN Competitors FULC Competitors TARA Competitors PBYI Competitors DERM Competitors OGI Competitors GLSI Competitors LYEL Competitors ACRS Competitors FDMT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNTX) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNTX Stock Free RNTX Stock Alerts